pre-IPO PHARMA

COMPANY OVERVIEW

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, endometrial, and ovarian cancers.


LOCATION

  • Philadelphia, PA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    http://www.contexttherapeutics.com


    CAREER WEBSITE

    http://www.contexttherapeutics.com/careers


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Oct 22, 2021

    Context Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option


    Mar 22, 2021

    Context Therapeutics Expands Board of Directors


    Jul 1, 2020

    Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results


    Jul 1, 2020

    Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results


    Mar 12, 2020

    Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER


    For More Press Releases


    Google Analytics Alternative